Skip to main content
main-content

04-06-2021 | ASCO 2021 | Conference coverage | Video

Patritumab deruxtecan shows promise for EGFR inhibitor-resistant NSCLC

Pasi Jänne shares updated phase 1 data on the antibody–drug conjugate patritumab deruxtecan in advanced EGFR-mutated non-small-cell lung cancer patients who have developed resistance to EGFR inhibitors (2:33).

Read transcript

Image Credits